pharmaceutical investing Ironwood and Alnylam Enter US GI Disease Education and Promotional Agreement
pharmaceutical investing Approval of Linzess Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation
pharmaceutical investing Ironwood Pharmaceuticals Initiates Phase IIIb Study of Linaclotide in Adult Patients with Irritable Bowel Syndrome with Constipation (IBS-C
Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease
Finlay Minerals: Advancing Strategic Copper-Gold-Silver Assets in British Columbia’s Toodoggone District
